Senzime AB (publ) (SEZI.ST)
SEK 5.64
(-1.05%)
SEK 5.64
(-1.05%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 20.34 Million SEK | -6.06% |
| 2022 | 21.65 Million SEK | 145.1% |
| 2021 | 8.83 Million SEK | 123.65% |
| 2020 | 3.95 Million SEK | 62.08% |
| 2019 | 2.43 Million SEK | 153.59% |
| 2018 | 961 Thousand SEK | -9.6% |
| 2017 | 1.06 Million SEK | 184.99% |
| 2016 | 373 Thousand SEK | -24.22% |
| 2015 | 492.2 Thousand SEK | 36.16% |
| 2014 | 361.49 Thousand SEK | -21.75% |
| 2013 | 462 Thousand SEK | 164.86% |
| 2012 | 174.43 Thousand SEK | 386.03% |
| 2011 | 35.88 Thousand SEK | -6.87% |
| 2010 | 38.53 Thousand SEK | -20.99% |
| 2009 | 48.77 Thousand SEK | -12.4% |
| 2008 | 55.67 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 22.16 Million SEK | 8.96% |
| 2024 Q2 | 25.63 Million SEK | 15.66% |
| 2023 FY | 20.34 Million SEK | -6.06% |
| 2023 Q4 | 20.34 Million SEK | -2.32% |
| 2023 Q1 | 22.17 Million SEK | 2.42% |
| 2023 Q2 | 20.25 Million SEK | -8.68% |
| 2023 Q3 | 20.82 Million SEK | 2.82% |
| 2022 Q3 | 18.06 Million SEK | 92.59% |
| 2022 Q4 | 21.65 Million SEK | 19.83% |
| 2022 Q1 | 9.6 Million SEK | 8.77% |
| 2022 FY | 21.65 Million SEK | 145.1% |
| 2022 Q2 | 9.38 Million SEK | -2.36% |
| 2021 FY | 8.83 Million SEK | 123.65% |
| 2021 Q2 | 6 Million SEK | -6.8% |
| 2021 Q1 | 6.44 Million SEK | 63.11% |
| 2021 Q3 | 8.57 Million SEK | 42.75% |
| 2021 Q4 | 8.83 Million SEK | 3.06% |
| 2020 Q2 | 1.77 Million SEK | -1.17% |
| 2020 Q1 | 1.79 Million SEK | -26.38% |
| 2020 FY | 3.95 Million SEK | 62.08% |
| 2020 Q4 | 3.95 Million SEK | 74.24% |
| 2020 Q3 | 2.26 Million SEK | 27.86% |
| 2019 Q4 | 2.43 Million SEK | 114.15% |
| 2019 FY | 2.43 Million SEK | 153.59% |
| 2019 Q2 | 1.89 Million SEK | -8.89% |
| 2019 Q1 | 2.08 Million SEK | 116.55% |
| 2019 Q3 | 1.13 Million SEK | -39.98% |
| 2018 Q3 | 848 Thousand SEK | -24.62% |
| 2018 Q2 | 1.12 Million SEK | 8.7% |
| 2018 FY | 961 Thousand SEK | -9.6% |
| 2018 Q4 | 961 Thousand SEK | 13.33% |
| 2018 Q1 | 1.03 Million SEK | -2.63% |
| 2017 Q1 | 357 Thousand SEK | -4.29% |
| 2017 Q2 | 1.07 Million SEK | 200.0% |
| 2017 Q3 | 1.08 Million SEK | 0.93% |
| 2017 Q4 | 1.06 Million SEK | -1.67% |
| 2017 FY | 1.06 Million SEK | 184.99% |
| 2016 Q4 | 373 Thousand SEK | -12.85% |
| 2016 Q3 | 428 Thousand SEK | -4.46% |
| 2016 FY | 373 Thousand SEK | -24.22% |
| 2016 Q2 | 448 Thousand SEK | 0.84% |
| 2016 Q1 | 444.28 Thousand SEK | -9.73% |
| 2015 FY | 492.2 Thousand SEK | 36.16% |
| 2015 Q3 | 475.01 Thousand SEK | -2.37% |
| 2015 Q4 | 492.2 Thousand SEK | 3.62% |
| 2015 Q1 | 359.95 Thousand SEK | -0.43% |
| 2015 Q2 | 486.55 Thousand SEK | 35.17% |
| 2014 FY | 361.49 Thousand SEK | -21.75% |
| 2014 Q4 | 361.49 Thousand SEK | -5.43% |
| 2014 Q3 | 382.25 Thousand SEK | 8.05% |
| 2014 Q2 | 353.77 Thousand SEK | 0.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2013 Q4 | 462 Thousand SEK | 0.0% |
| 2013 Q2 | 584.16 Thousand SEK | 0.0% |
| 2013 Q1 | 584.16 Thousand SEK | 234.9% |
| 2013 FY | 462 Thousand SEK | 164.86% |
| 2012 Q4 | 174.43 Thousand SEK | 0.0% |
| 2012 FY | 174.43 Thousand SEK | 386.03% |
| 2012 Q2 | 58.5 Thousand SEK | 0.0% |
| 2011 FY | 35.88 Thousand SEK | -6.87% |
| 2011 Q4 | 35.88 Thousand SEK | 0.0% |
| 2011 Q2 | 38.53 Thousand SEK | 0.0% |
| 2010 Q4 | 38.53 Thousand SEK | 0.0% |
| 2010 Q2 | 46.5 Thousand SEK | 0.0% |
| 2010 FY | 38.53 Thousand SEK | -20.99% |
| 2009 Q4 | 48.77 Thousand SEK | 0.0% |
| 2009 FY | 48.77 Thousand SEK | -12.4% |
| 2008 FY | 55.67 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | -197.412% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 83.218% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 83.218% |
| Arcoma AB | 28.02 Million SEK | 27.427% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | 31.39% |
| BICO Group AB (publ) | 493.1 Million SEK | 95.875% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 67.404% |
| CellaVision AB (publ) | 126.03 Million SEK | 83.862% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | -232.625% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | -1048.555% |
| C-Rad AB (publ) | 64.09 Million SEK | 68.268% |
| Duearity AB (publ) | 4.15 Million SEK | -389.06% |
| Dignitana AB (publ) | 7.41 Million SEK | -174.383% |
| Episurf Medical AB (publ) | 3.7 Million SEK | -449.73% |
| Getinge AB (publ) | 6.41 Billion SEK | 99.683% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 1308.29% |
| Iconovo AB (publ) | -4.86 Million SEK | 518.346% |
| Integrum AB (publ) | 22.36 Million SEK | 9.042% |
| Luxbright AB (publ) | 8000.00 SEK | -254150.0% |
| Mentice AB (publ) | 14.1 Million SEK | -44.214% |
| OssDsign AB (publ) | 4.3 Million SEK | -372.584% |
| Paxman AB (publ) | 19.99 Million SEK | -1.705% |
| Promimic AB (publ) | 330 Thousand SEK | -6063.636% |
| Qlife Holding AB (publ) | 7.29 Million SEK | -178.936% |
| SciBase Holding AB (publ) | 11.91 Million SEK | -70.652% |
| ScandiDos AB (publ) | 22.69 Million SEK | 10.357% |
| Sectra AB (publ) | 36.59 Million SEK | 44.411% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 52.67% |
| SpectraCure AB (publ) | 1.00 SEK | -2033999900.0% |
| Stille AB | 66.55 Million SEK | 69.438% |
| Vitrolife AB (publ) | 413 Million SEK | 95.075% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 85.636% |